Tissue Repair, IsASL Annual Conference
June 16th – 18th 2016
The Dan Hotel Eilat (Red Sea)

Scientific Program

Sponsored by:

Platinum
Gilead

Gold
Abbvie
Bristol-Myers Squibb
MSD

Silver
Abbott
Novartis
A.S.

Bronze
MegaPharm
Yazalex
Kamada

לنتقلים אל סרטי הקוד:

![QR Code]
Thursday 16/6/2016

10:00-10:30   Light breakfast & exhibition

10:30-13:10   SESSION 1: THE JUNE LIVER FORUM
Moderator: Yoav Lurie & Rifaat Safadi

10:30-11:00  Case Presentation & Discussion 1, Rambam, Haifa
11:00-11:10  Case Presentation & Discussion 2, Bnei Zion, Haifa
11:10-11:40  Case Presentation & Discussion 3, Kaplan, Rehovot
11:40-12:10  Case Presentation & Discussion 4, Hadassah, Jerusalem
12:10-12:40  Case Presentation & Discussion 5, Barzilay, Ashkelon
12:40-13:10  Case Presentation & Discussion 6, Rambam, Haifa

Sponsored by Abbvie

13:10-13:45   Light Lunch & Exhibition

PARALLEL SESSION

13:45-14:00  TISSUE REPAIR OPENING
IsASL Chairman: Rifaat Safadi

14:00-15:14  SESSION 2: THE 2016 CHALLENGES IN VIRAL HEPATITIS
Chairs: Amir Shlomai & Michal Carmiel

14:00-14:20  Translating molecular virology into novel antiviral therapies
Jeffrey Glenn, Associate Professor of Medicine and Microbiology & Immunology, Division of Gastroenterology and Hepatology, Director, Center for Hepatitis and Liver Tissue Engineering, Stanford University School of Medicine

14:22-14:30  Hepatitis B virus antagonizes sorafenib in hepatoma cells through indirect induction of the Raf-Mek-Erk pathway
Amir Shlomai1,2, Dvora Witt-Kehati2, Romy Zemel2
1 Department of Medicine D, Beilinson hospital, 2 Felsenstein Medical Research Center, The Faculty of Medicine, Tel-Aviv University
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:32-14:36</td>
<td>Regression of Liver Fibrosis assessed by non-invasive methods in</td>
<td>Davidov Yana¹, Klienboum Yoram², Cohen-Ezra Oranit¹, Veitsman Ella¹, Berdichevsky Tanya¹, Weiss Perez¹, Katerginsky</td>
<td>Liver Disease Center, Department of Radiology Sheba Medical Center, Tel Hashomer, Ramat Gan, Sackler School of Medicine, Tel Aviv University</td>
</tr>
<tr>
<td></td>
<td>Patients with Chronic Hepatitis C who Achieved Sustained Virologic</td>
<td>Sima², Hassid Avishag³, Tzaraf Keren¹, Ben-Ari Ziv¹,³</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Response after DAAs Treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:37-14:41</td>
<td>Beneficial outcomes of DAA’s on post SVR liver stiffness</td>
<td>Saleh Daher¹, Nadav Ilani¹, Tawfik Khouri¹, Mina Rowe¹, Rifaat Safadi¹</td>
<td>The Liver Unit, Institute of Gastroenterology and hepatology, Hadassah-Hebrew University Medical Center, Jerusalem</td>
</tr>
<tr>
<td>14:42-14:46</td>
<td>Hepatitis C virus induces oncogenic signatures that are not fully</td>
<td>Shira Perez¹, Antony Kaspi³, Ateret Davidovich¹, Assy Nimer⁴, Izhak Haviv², Meital Gal-Tanamy¹</td>
<td>Molecular Virology Lab, Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Cancer Personalized Medicine and Diagnostic Genomics Lab, Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Epigenetics in Human Health and Disease Laboratory, Baker IDI Heart &amp; Diabetes Institute, Melbourne, Galilee Medical Centre, Nahariya</td>
</tr>
<tr>
<td></td>
<td>reverted following treatment with DAAs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:47-14:51</td>
<td>The Efficacy and Safety of Different Direct-Acting Antiviral Agents</td>
<td>Ella Weitzman¹, Lichter Maria¹, Keren Tsaraf¹, Ardita Jonuzi¹, Peretz Weiss¹, Orna Mor²,³, Ziv Ben-Ari¹,³</td>
<td>Center for liver diseases, Sheba Medical Center, Central Virology Laboratory, Ministry of Health, Ramat Gan, Sackler School of Medicine, Tel Aviv University, Tel Aviv</td>
</tr>
<tr>
<td></td>
<td>in Liver Transplant Recipients with Recurrent Hepatitis C: A Single</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Center Study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:52-15:12</td>
<td>Harvoni Real Life German Data</td>
<td>Peter Buggisch, Head of Liver Center Hamburg, IFI at the Asklepiosklinik St. Georg Haus L</td>
<td></td>
</tr>
</tbody>
</table>

Sponsored by GILEAD
SESSION 3: NURSES WORKSHOP I, DAA’S ADHERENCE
Chairman: Matthias Carlebach & Rimma Kramsky

13:45-14:00钟
افتتاح שירותים כבדים בבי”ח העמק
by Alexander Shtrikman, מהכנה להשתללות, מנקודות המבט של המטופל והצוות

14:00-14:15钟
רמב"ם
רימה קרמסקי, עמותת חץ - עמותת חץ, הווה ועתיד בפעילויות בארץ

14:15-14:30钟
Sponsored by

SESSION 4: ABSTRACTS PRESENTATION & DEBATE: ANTIMCOAGULATION AND CHIROSSIS
Chairman: Assy Nimmer & Tarek Saadi

15:14-15:24钟
Debate:
Pro - Amir Shlomai
Con - Michal Carmiel

15:25-15:33钟
Genomic signatures of Hepatitis viruses in liver cancer
Shira Perez1,2, Anat Lavi-Izkovitz3, Gur Yaari3, Ana Tover4, Salomon M Stemmer4, Izhak Haviv2, Meital Gal-Tanamy1
1 Molecular Virology Lab, Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, 2 Cancer Personalized Medicine and Diagnostic Genomics Lab, Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, 3 Systems computational biology, Faculty of Engineering, Bar-Ilan University, Ramat-Gan
4 Davidoff Center, Tel-Aviv University, Rabin Medical Center, Beilinson Campus, Petach Tikva

15:34-15:42钟
Sortilin deficiency reduces ductular reaction, hepatocyte apoptosis and liver fibrosis in cholestatic-induced liver injury
Isabel Zvibel1*, Einav Hubel1, Ashish Saroha2, Woo-Jae Park3, Yael Pewzner-Jung2, Elise G Lavoie4, Anthony H Futerman2, Rafael Bruck1, Sigal Fishman1, Jonathan A Dranoff4, Oren Shibolet1*
1 The Research Center for Digestive Tract and Liver Diseases, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, 2 Department of Biological Chemistry, Weizmann Institute of Science, Rehovot, 3 Department of Biochemistry, School of Medicine, Gachon University, 4 Division of Gastroenterology & Hepatology, University of Arkansas for Medical Sciences
15:43-15:55  NK cells from homozygous NLG4-/-(KO) mice inhibit liver fibrosis through PI3K/AKT/mTOR pathway and decreased interleukin-4

Rifaat Safadi, Johnny Amer, Ahmad Salhab,
Liver Unit, Gastroenterology and Liver Diseases, Hadassah-Hebrew University Medical Center, Jerusalem

15:56-16:04 Improvement in Non-Invasive Hepatic Parameters of Nonalcoholic Fatty Liver Disease in Obese Uncontrolled T2DM Patients who underwent Endoscopic Duodenal-Jejunal Bypass Liner (Endobarrier) Implantation

Oranit Cohen-Ezra1, G Segal-Liberman2, A Lang3, M Lahav3, Y Kleinbaum4, Y Inbar4, S Katscherginsky4, E Veitsman1, T Bradichevsky1, P Weiss1, K Tsaraf1, Z Ben-Ari1
1 liver disease center, sheba medical center, Ramat Gan
2 Endocrine institute, sheba medical center, Ramat Gan
3 Gastroenterology institute, sheba medical center, Ramat Gan

16:04-16:08 Effects of anti-hypertensive and triglyceride lowering agents on hepatic copper concentrations in rats with fatty liver disease

Zvi Ackerman1, Galina Skarzinski2, Maria Grozovski3, Mor Oron-Herman4, Ben-Ami Sela4
1 Department of Medicine, Hadassah-Hebrew University Medical Center, 2 Department of Pathology, Hadassah-Hebrew University Medical Center, 3 Department of Human Nutrition and Metabolism, Hebrew University- Hadassah Medical School, 4 Biotechnology, Ort Braude College of Engineering, Karmiel

16:09-16:13 The effects of iron overload on acetaminophen hepatotoxicity in rats

Zvi Ackerman1, Galina Skarzinski2, Gabriela Link3, Maya Glazer1, Orit Pappo2, Maria Grozovski4
1 Department of Medicine, Hadassah-Hebrew University Medical Center, 2 Department of Pathology, Hadassah-Hebrew University Medical Center, 3 Department of Human Nutrition and Metabolism, Hebrew University- Hadassah Medical School, 4 Biotechnology, Ort Braude College of Engineering, Karmiel
16:14-16:22  Batf3 Dependent

Dendritic cells are crucial for Primary Biliary Cholangitis
Ehud Zigmond1, Debby Reuveni1, Yael Gore1, Patrick Leung2, Eli Brazowski1, Zamir Halpern1, Oren Shibolet1, Eric Gershwin2
1 Research Center for Digestive Diseases, Sourasky Medical Center and Sackler Faculty of Medicine, Tel-Aviv,
2 Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis

16:23-16:31  Detected HCV RNA at the end of treatment with DAAs does not reduce the possibility to achieve SVR

Tarek Saadi1, Rawi Hazzan2, Yelena Yermenko2, Michal Carmiel3, Matthias Carlebach4, Rimma Kramskay1, Vered Ben-Hakoon1, Bella Smolen1, Hisham Sholy1, Johad Khoury1, Yaacov Baruch1
1 Liver Units, Rambam-Health Care Campus, Haifa; 2 Liver Unit, HaEmek Medical Center, Afula; 3 Liver Unit, Western Galilee Hospital, Nahariya; 4 Bnai-Zion, Medical Center, Haifa.

16:32-17:00  Coffee Break & Exhibition

17:00-17:18  SESSION 5: ACUTE AND / ON CHRONIC LIVER FAILURE

Chairman: Yoram Menachem & Marius Braun

17:00-17:18  Hepatic decompensation during DAAs therapy in advanced HCV cirrhosis
Ziv Ben Ari, Director Liver Disease Center, Sheba Medical Center, Tel Hashomer

17:20-17:24  Acute Coronary Syndromes in patients with Non-alcoholic Fatty Liver Disease (NAFLD)
Yaakov Maor1, Dan Haberman2, Ehud Melzer1, Jacob George2
1 Institute of Gastroenterology and Hepatology, Kaplan Medical Center, Rehovot, 2 Heart Center, Kaplan Medical Center, Affiliated to the Hebrew university, Jerusalem, Rehovot

17:25-17:29  Non-alcoholic Fatty Liver Disease in Young Adults-Epidemiologic Data from a Large Cohort

Yaakov Maor1, Salah Daher2,3, Eran Israeli3, Lior Katz2,4
1 Institute of Gastroenterology and Hepatology, Kaplan Medical Center, Rehovot, 2 Israeli Defense Force, Israeli Defense Force, 3 Department of Gastroenterology and Hepatology, Hadassah Medical Center, Jerusalem, 4 Department of Gastroenterology, Sheba Medical Center, Tel-Hashomer
17:30-17:34 Unexpected diagnosis of Hepatocellular Carcinoma (HCC) soon after all oral (DAA) therapy for hepatitis C virus (HCV)
Marius Braun1,2, Michal Cohen Naftali1,2, Yfaat Snir1,2, Orly Sneh Arbib1,2, Amir Shlomai1,2, Ofer Beniaminov2,3, Salomon Stermer2,4, Ran Tur Kaspa1,5
1 Liver Institute, Beilinson Hospital, Petah Tikva, Israel
2 Sackler School of Medicine, Tel Aviv University, Israel
3 Imaging department, Beilinson Hospital, Petah Tikva, Israel
4 Oncology department, Beilinson Hospital, Petah Tikva, Israel
5 Faculty of Medicine of Bar-Ilan University in the Galilee, Safed

17:35-17:39 The role of hepatic microenvironment in growth and metastasis of hepatitis c virus - induced hepatocellular carcinoma
Abraham Nissani1, Liat Ninio1, Ateret Davidovich1, Mark Shlapobersky2, Anastasia Malek3, Izhak Haviv2, Hava Gil-Henn3, Meital Gal-Tanamy1
1 Laboratory of molecular virology, Faculty of Medicine in the Galilee, Bar-Ilan University, Safed,
2 Laboratory of cancer research, Faculty of Medicine in the Galilee, Bar-Ilan University, Safed,
3 Laboratory of cell migration and invasion, Faculty of Medicine in the Galilee, Bar-Ilan University, Safed

17:40-17:44 The interplay between Hepatitis C virus infection, changes in higher chromatin organization and cancer
Meital Gal-Tanamy1, Michael Gevor1, Shira Perez1, Antony Kaspi2, Ateret Davidovich1, Izhak Haviv1, Itay Onn1,
1 Faculty of Medicine in the Galilee, Bar-Ilan University,
2 Epigenetics in Human Health and Disease Laboratory, Baker IDI Heart & Diabetes Institute

17:45-18:10 Acute Liver Failure: Causes and Consequences
Adrian Reuben, Medical University of South Carolina (MUSC), Charleston SC, USA

19:30 Dinner
Friday 17/6/2016

07:30  Breakfast with Visitors, F:F meeting

08:00-09:00  SESSION 6: NURSES WORKSHOP II, DAA'S ADHERENCE
Chairman: Alice Herskovic & Orly Azulay

08:00-08:15 实际行动对治疗病人的影响
Marina Libiszewski Ajshilov

08:15-08:30 通过无创性HCV对患者的满意度和结果
Ely Herif Blinsot

08:30-08:45 以色列与欧盟在HCV治疗的比较
Korn Zarif, merzly lehatol boded shel shomer

08:45-09:00 末梢护士在新治疗中的作用
Dr. Gili Nitzan, Gilead

Sponsored by Gilead

08:00-10:00  SESSION 7: PEDIATRIC HEPATOLOGY: METABOLIC DISORDERS
Chairman: Tania Berdichevski & Rifaat Safadi

08:00-08:18  pediatric liver transplantations – Indications and outcome
Dr. Yael Mozer, Schneider Children’s Hospital

08:20-08:28  Challenging the current normal range of serum alanine aminotransferase in the elderly - a need for reevaluation
Schmilovitz-Weiss Hemda1,2, Rachel Gingold-Belfer1,2, Yichayaou Beloosesky1,2, Joseph Meirowitz2, Nira Koren-Morag2, Avraham Weiss1,2
1 Gastroenterology, Rabin Medical Center, Petach-Tiqwa
2 Sackler faculty of medicine, Tel Aviv University, Tel Aviv

08:30-08:38  The association of ALT levels with myocardial perfusion imaging and cardiovascular morbidity.
David Yardeni1, Ohad Etzion1,4, Ronen Toledano2, Victor Novack2, Aryeh Shalev3, Arik Wolak3, Yaron Rotman4
1 Gastroenterology and Liver Disease Institute, Soroka University Medical Center, 2 Clinical Research Center, Soroka University Medical Center, 3 Cardiology Section, Soroka University Medical Center, 4 Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:40-08:58</td>
<td>The role of Whole Exome Sequencing in diagnosis of liver diseases</td>
<td>Orli El Peleg, Hadassah Medical Center</td>
</tr>
<tr>
<td>09:00-09:04</td>
<td>Thiopurine Metabolite Assessment in children with Autoimmune Hepatitis</td>
<td>Eyal Shteyer¹, Jahjah Elias¹, Orit Pappo², Ledder Oren¹, Raffi Lev-Tzion¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹Pediatric Gastroenterology institute, Shaare Zedek Medical Center, Jerusalem, ²Departament of Pathology, Hebrew University-Hadassah Medical Center, Jerusalem</td>
</tr>
<tr>
<td>09:05-09:09</td>
<td>New ultrasonographic protocol for early diagnosis of cystic fibrosis liver disease</td>
<td>Eyal Shteyer⁵, Or Steg Saban¹, Michael Wilschanski¹, Moti Menachem¹, Natasha Simanovski², Eitan Kerem¹, Deirdre Kelly⁴, Louis Stewart⁴</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹Pediatric Gastroenterology Unit, ²Radiology Department, ³Department of Pediatrics, Hebrew University-Hadassah Medical Center, Jerusalem, ⁴Liver Unit, Birmingham Children’s Hospital, Birmingham, ⁵Pediatric Gastroenterology institute, Shaare Zedek Medical Center, Jerusalem</td>
</tr>
<tr>
<td>09:10-09:28</td>
<td>MiRNA tools in diagnosis and treatment of liver diseases</td>
<td>Shimon Reif, Hadassah Medical Center</td>
</tr>
<tr>
<td>09:30-09:34</td>
<td>ADAR1 knockdown HepG2 cells directly affect the activation of primary HSCs via the up-regulation of IL-6</td>
<td>Michal Safran¹, Polina Kagan¹, Shirley Oren², Maya Sultan¹, Ziv Ben-Ari¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td>¹Liver Research Laboratory, Chaim Sheba Medical Center, Ramat Gan, ²Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan, ³Liver Disease Center, Chaim Sheba Medical Center, Ramat Gan, ⁴The Sackler School of Medicine, Tel Aviv University, Tel-Aviv</td>
</tr>
<tr>
<td>09:35-09:39</td>
<td>CD49a- CD49b+ NK1.1 cells in C57/BL fibrotic livers are distinct from peripheral NK cells in their neurologin4/CD107a activatory marker</td>
<td>Johnny Amer, Ahmad Salhab, Rifaat Safadi</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Liver Unit, Gastroenterology and Liver Diseases, Hadassah-Hebrew University Medical Center, Jerusalem</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>09:40-09:58</td>
<td>Characteristics of Cholestatic liver disease in Pediatrics.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Efrat Broide</strong>, Assaf Harofe Medical Center</td>
<td></td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee Break &amp; Exhibition</td>
<td></td>
</tr>
<tr>
<td>10:30-11:45</td>
<td><strong>SESSION 8: NUTRITION AND LIVER DISEASE</strong></td>
<td></td>
</tr>
<tr>
<td>10:30-10:48</td>
<td><strong>Nutrition in Cirrhosis</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Shibolet Oren</strong>, Director of the Liver Unit, Department of</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gastroenterology, Tel-Aviv Medical Center and Tel-Aviv University</td>
<td></td>
</tr>
<tr>
<td>10:50-11:08</td>
<td><strong>Nutrition &amp; Acute Liver States</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Rifaat Safadi</strong>, Liver &amp; Gastroenterology Units, Hadassah-Hebrew</td>
<td></td>
</tr>
<tr>
<td></td>
<td>University Hospital</td>
<td></td>
</tr>
<tr>
<td>11:10-11:18</td>
<td><strong>Baseline and treatment failure resistance analysis in HCV GT1</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>patients treated with first and second generation direct acting</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>antivirals</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Yael Gozlan</strong>1, Ziv Ben Ari2,3, Rachel Shirazi1, Roy Moscona1, Avia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rakovsky1, Ella Weitzman2,3, Tania Bradichevsky2,3, Peretz Weiss2,3,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Avishag Hassid2, Keren Tsaraf2, Yoav Luria4, Oren Shibolet3, Eli</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zuckerman4,7, Marius Brown3,8, Michal Cohen-Naftali3,8, Ofer Peleg9,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ella Mendelson1, Orna Mor1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 Central Virology Laboratory, Ministry of Health, 2 Liver Disease</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Center, Sheba Medical Center, 3 Faculty of Medicine, Sackler</td>
<td></td>
</tr>
<tr>
<td></td>
<td>faculty of Medicine, Tel Aviv University, 4 Liver unit, Shaare Zedek</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medical Center, 5 Department of Gastroenterology, Tel-Aviv Medical</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Center, 6 Liver Unit, Carmel Medical Center, 7 Rappaport Faculty of</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Medicine, The Technion, 8 Liver Institute, Rabin Medical Center, 9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Genaphora, Genaphora, 10 School of Public Health, Tel Aviv University</td>
<td></td>
</tr>
<tr>
<td>11:20-11:24</td>
<td><strong>Unique clinical features of Non Alcoholic Steato Hepatitis</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(NASH)-related hepatocellular carcinoma (HCC)**</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Yoram Menachem</strong>1, Oren Shibolet1, Izhar Levy 2, Rifaat Safadi2,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eli Zuckerman3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1 Tel Aviv Sourasky Medical Center, 2 Hadassah University Hospital</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jerusalem, 3 Carmel Hospital, Haifa</td>
<td></td>
</tr>
</tbody>
</table>
HBV down regulates the expression levels of vitamin d receptor in hepatocellular carcinoma transfected cells thereby preventing inhibition of viral replication by Vitamin D

Michal Safran¹, Neta Gotlieb¹, Irina Tachlytski¹, Lena Lapidot¹,³, Maya Sultan¹, Ziv Ben Ari¹,²,³
¹ Liver Research Laboratory, Sheba Medical Center, Ramat Gan, ² Liver Disease Center, Sheba Medical Center, Ramat Gan ³ The Sackler School of Medicine, Tel Aviv University

Enhancing patients’ knowledge and accessibility to healthcare services increase implementation of hepatitis C virus therapy in methadone maintenance treatment patients

Einat Peles¹, Miriam Adelson¹, Anat Sason¹, Helena Katchman², Stella Levit², Shaul Schreiber¹, Oren Shibolet² and Rafael Bruck²
¹ Dr. Miriam & Sheldon G. Adelson Clinic for Drug Abuse Treatment & Research, ² Liver Unit, Department of Gastroenterology, Tel-Aviv Medical Center & Sackler Faculty of Medicine, Tel Aviv University

Israeli’s and global lessons extracted from the HCV Quest Global Patient Survey

Ziv Ben-Ari¹,³,⁴, Hulio Burman², Keren Tsaraf¹, Charles Gore³

Autoimmune hepatitis: a single center experience with a long follow-up

Eli Zuckerman¹, Yulia Kovalev¹, Eyal Ashkenasie¹

SESSION 9: THE 2016 CHALLENGES IN VIRAL HEPATITIS

Chairman: Dani Shoval & Yaacov Maor

HCV treatment in special populations

Didier Samuel, Professor of Hepatology and Gastroenterology at Université Paris-Sud, Villejuif, France

Sponsored by MSD

The HCV real life in Israel

Prof. Eli Zuckerman
12:34-12:42  **Hepatitis E in Israel**  
Orna Mor¹, Daniela Ram¹, Yossi Manor¹, Yael Gozlan¹, Eli Schwartz², Ziv Ben-Ari³, Ella Mendelson¹, Shaul Possi⁴  
¹Central Virology Laboratory, Ministry of Health, ²Center for Geographic Medicine and Tropical Diseases, Chaim Sheba Medical Center, ³Liver Diseases Center, Chaim Sheba Medical Center

12:43-12:51  **Hepatitis E in haematological patients in Israel**  
Rasha Daniel¹,⁴,⁵, Tsila Zuckerman², Shira Zelber-Sagi³,⁵, Mira Barak⁴, Orly Azulay¹, Eli Zuckerman¹  
¹Liver Unit, Carmel Medical Center, Haifa, Haifa and Western Galilee District, ²BMT Unit, Department of Hematology, Rambam Medical Center, Haifa, ³Department Gastroenterology, Tel-Aviv Medical Center, ⁴Nesher Central Laboratories, CHS, Haifa and Western Galilee District, ⁵Faculty of Public Health, Haifa University

12:52-12:56  **The Prevalence Of Hepatitis E Virus Antibodies In Israel**  
Rasha Daniel¹,³,⁴, Shira Zelber-Sagi²,³, Mira Barak³, Orly Azulay¹, Eli Zuckerman¹  
¹Liver Unit, Carmel Medical Center, ²Department Gastroenterology, Tel-Aviv Medical Center, ³Nesher Central Laboratories, CHS, Haifa and Western Galilee District, ⁴Faculty of Public Health, Haifa University

12:57-13:01  **Patients’ age rather than their Model of End-stage Liver Disease (MELD) score predicts long-term survival after liver transplantation**  
Yaara Leibovici-Weissman¹,³, Moshe Leshno³, Amir Shlomi¹,²,⁴  
¹Sackler Faculty of Medicine, Tel-Aviv University, ²Department of Medicine D, Beilinson hospital, ³School of Management, Tel-Aviv University, ⁴The Liver Institute, Beilinson hospital

13:02-13:22  **Prenylation inhibitors for treating delta hepatitis**  
Jeffrey Glenn, Associate Professor of Medicine and Microbiology & Immunology, Division of Gastroenterology and Hepatology, Director, Center for Hepatitis and Liver Tissue Engineering, Stanford University School of Medicine

13:30-13:40  **IsASL Business Meeting:**  
IsASL Governing Board  
Rifaat Safadi, Chairman  
Tania Berdichevski, Treasurer  
Matthias Carlebach, Observer

13:40  **Closing Remarks:**  
Rifaat Safadi, IsASL Chairman

14:00  Lunch